Entering text into the input field will update the search result below

GSK submits regulatory application for Tafenoquine for the treatment of Plasmodium vivax malaria to Australia’s TGA

  • GlaxoSmithKline (NYSE:GSK), in partnership with Medicines for Malaria Venture (MMV), submits a regulatory application to the Australian Therapeutics Good Administration (TGA) seeking approval of single-dose tafenoquine treatment for the radical cure (prevention of relapse) of Plasmodium vivax (P. vivax) malaria.
  • If approved, tafenoquine would be the first new medicine for the prevention of relapse of P. vivax malaria in more than 60 years.
  • GSK plans to progress regulatory filings in other countries in 2018.
  • Shares are up a fraction on light volume.

Recommended For You

About GSK Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
GSK--
GSK plc